AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 https://ow.ly/CNZx50SpyNJ
AbCellera
Biotechnology Research
Vancouver, British Columbia 34,511 followers
Antibody discovery engine
About us
AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.
- Website
-
http://www.abcellera.com
External link for AbCellera
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2012
- Specialties
- Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell engagers, and Bispecifics
Locations
-
Primary
Get directions
2215 Yukon St
Vancouver, British Columbia V5Y, CA
-
Get directions
91 Mystic St
Arlington, Massachusetts 02474, US
-
Get directions
41-45 Bourke Rd
Alexandria, New South Wales 2015, AU
-
Get directions
7236 Rue Waverly
Montreal, Quebec H2R 0C2, CA
Employees at AbCellera
Updates
-
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 https://ow.ly/t1Lh50RZ0fi
-
-
Congratulations to our partner, Abdera Therapeutics, on receiving FDA clearance for its IND application for ABD-147, an antibody-based precision radiotherapeutic targeting small cell lung cancer and large cell neuroendocrine carcinoma. https://lnkd.in/esxvb9dQ
-
-
Congratulations to Arsenal Biosciences, Inc., who in April announced the First Patient Dosed in Phase 1/2 for AB-2100 in development as a treatment for clear-cell renal cell carcinoma. https://lnkd.in/gtNyhKKh
-
-
See us at #PEGSBoston to learn about our T-cell engagers targeting prostate-specific membrane antigen (PSMA) that showed significantly lower cytokine release compared to clinical benchmarks.
-
-
AbCellera Reports Q1 2024 Business Results https://ow.ly/6aAy50RyVk4
-
-
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies https://ow.ly/Ql1K50RtqNW
-
-
Congratulations to Andrew Booth, AbCellera's CFO, who is a recipient of The Globe and Mail's Report on Business 2024 Best Executive Awards. Canada is at an inflection point. We have an opportunity to build, from the ground up, a life sciences ecosystem that will make our communities stronger, bring new medicines to patients, and create a legacy of innovation for generations to come. Thank you for leading us to today and paving the path for tomorrow. https://lnkd.in/gMz3Za_M
-